Health Canada greenlights Arexvy, the inaugural respiratory syncytial virus (RSV) vaccine for seniors aged 60 and above. Amid calls from doctors for an RSV vaccine targeting seniors, the approval marks a crucial step. However, limited utilization anticipated during the upcoming respiratory virus season. GSK's Arexvy demonstrates promise, boasting an 82% prevention rate for RSV-induced lower respiratory tract issues in a recent trial. The RSV season spans late fall through spring in Canada.
We'll keep you updated on all new application updates and features!